Mycoplasma infections respiratoires

Mycoplasma sp.: Characteristics, Pathogenicity, Diagnosis, and Treatment

Mycoplasma species are unique bacteria belonging to the class Mollicutes, a name derived from the Latin "mollis" (soft) and "cutis" (skin), aptly describing their flexible nature due to the absence of a rigid cell wall. This fundamental characteristic distinguishes them from most other bacteria and dictates many of their biological properties and their interaction with host organisms.

Understanding Mycoplasma is crucial in clinical microbiology due to their role in various human diseases, particularly respiratory and urogenital tract infections. This note will provide a comprehensive overview of their characteristics, the mechanisms by which they cause disease, diagnostic approaches, and treatment principles.

1. Characteristics of Mycoplasma sp.

Mycoplasmas possess several distinctive features that set them apart from other bacteria.

1.1. Structural and Morphological Peculiarities

• Lack of a Cell Wall: This is the most defining characteristic of Mycoplasma. Unlike other bacteria, they do not have a peptidoglycan cell wall. This absence makes them naturally resistant to beta-lactam antibiotics (which target cell wall synthesis) and results in their highly pleomorphic (variable) morphology. They can appear coccoid, filamentous, or even branched.
• Smallest Free-Living Prokaryotes: Mycoplasmas are among the smallest known prokaryotes capable of autonomous multiplication, typically ranging from 0.3 to 0.85 μm in size.
• Sterol-Containing Membrane: Their cell membrane is unique among prokaryotes in that it incorporates sterols (like cholesterol) from the host environment. This sterol requirement makes their membrane more stable but also contributes to their fastidious growth requirements and fragility outside of the host.
• Internal Structure: Despite their small size, they contain essential components such as ribosomes, soluble RNA, DNA, soluble proteins, and a lipoprotein membrane.

1.2. Growth and Metabolic Requirements

• Facultative Anaerobes: Most Mycoplasma species can grow in both aerobic and anaerobic conditions, though many prefer reduced oxygen levels (10-15% ).
• Temperature and pH: Optimal growth generally occurs at and a pH of 7.4-7.8.
• Fastidious Nature: Their reliance on preformed molecules from their host (e.g., sterols, fatty acids, amino acids, nucleic acid precursors) makes them nutritionally demanding.
• Specialized Media: Due to their complex nutritional needs, Mycoplasma species require highly enriched specialized media for cultivation. Examples include SP-4, PPLO (pleuropneumonia-like organisms) medium, and modified Hayflick's medium.
• Slow Growth: Mycoplasma species typically exhibit a slow growth rate, often taking days to weeks to form visible colonies. For instance, M. pneumoniae can take 6 to 20 days to grow in culture.
• Non-motile and Non-spore-forming: Mycoplasmas lack flagella or other motility structures and do not form spores.

1.3. Habitat and Transmission

• Strictly Host-Associated: Mycoplasmas are obligate parasites and are tightly associated with their host organisms, colonizing mucosal surfaces. They do not have an environmental reservoir.
• Respiratory Tract: Mycoplasma pneumoniae is a strict human respiratory tract pathogen.
• Urogenital Tract: Mycoplasma genitalium and Mycoplasma hominis are common colonizers of the urogenital tract and can act as opportunistic pathogens. Ureaplasma urealyticum also falls into this category.
• Transmission Routes:
  • Respiratory Droplets: M. pneumoniae spreads through respiratory droplets and aerosols, making close contact a primary mode of transmission.
  • Sexual Transmission: M. genitalium and M. hominis are transmitted sexually.
  • Vertical Transmission: From mother to child, particularly for urogenital species.

Some Mycoplasma species can be asymptomatic colonizers, complicating diagnosis and understanding their exact pathogenic role in certain conditions.

2. Pathogenicity and Virulence Factors

Mycoplasmas cause disease through various mechanisms, primarily by adhering to host cells, evading the immune system, and producing toxins. They are obligate parasites, meaning they are host-dependent for metabolism and survival.

2.1. Key Virulence Factors

• Adhesins: Mycoplasmas possess specialized adherence proteins and organelles that allow them to tightly bind to host epithelial cells, particularly ciliated cells in the respiratory tract. This cytadherence is crucial for colonization and initiating infection.
• Variable Surface Proteins (VSPs): These proteins undergo antigenic variation, allowing Mycoplasmas to evade the host immune response by changing their surface antigens.
• CARDS Toxin: The Community-Acquired Respiratory Distress Syndrome (CARDS) toxin is a potent ADP-ribosylating toxin produced by M. pneumoniae. It contributes to inflammation and cellular damage in the respiratory tract, potentially leading to airway hyperreactivity.
• Hydrogen Peroxide Production: Mycoplasmas can produce reactive oxygen species, including hydrogen peroxide, which can cause oxidative damage to host cells and impair ciliary function.
• Biofilm Formation: The ability to form biofilms enhances their survival, protects them from antibiotics, and contributes to chronic infections.
• Intracellular Survival: Some Mycoplasma species, including M. pneumoniae, can invade and survive within host cells, which provides a sanctuary from immune surveillance and antibiotics. This involves processes like invagination, coated vesicle formation, endosome trafficking, and even nuclear localization.

2.2. Clinical Manifestations

Mycoplasma infections can range from asymptomatic colonization to severe systemic diseases.

• Mycoplasma pneumoniae: Primarily affects the respiratory tract.
  • Atypical Pneumonia: Often referred to as "walking pneumonia," it is the second most common cause of community-acquired pneumonia after Streptococcus pneumoniae. Symptoms are typically milder than bacterial pneumonia and may include persistent cough, fever, and chest pain.
  • Upper Respiratory Tract Infections: Can cause pharyngitis (sore throat) and otitis media (inflammation of the ear).
  • Extrapulmonary Manifestations: Can trigger autoimmune phenomena, such as the production of cold agglutinins, which can lead to hemolytic anemia. Neurological complications, dermatological rashes, and cardiac involvement are also possible.
• Mycoplasma hominis: Mainly associated with urogenital infections.
  • Pelvic Inflammatory Disease (PID): An infection of the female reproductive organs.
  • Pyelonephritis: Kidney infection.
  • Spontaneous Abortion: Implicated in adverse pregnancy outcomes.
  • Postpartum Fever: Fever after childbirth.
• Ureaplasma urealyticum: Also affects the urogenital tract.
  • Non-Gonococcal Urethritis (NGU) in Men: A common cause of urethral inflammation not caused by gonorrhea.
  • Pelvic Inflammatory Disease (PID): Similar to M. hominis.
  • Can also cause complications in neonates, such as pneumonia and meningitis, especially in premature infants.

3. Diagnosis of Mycoplasma Infections

Diagnosing Mycoplasma infections can be challenging due to their fastidious nature, slow growth, and often non-specific symptoms. A combination of direct and indirect methods is typically employed.

3.1. Direct Diagnosis

Direct methods aim to detect the organism itself or its genetic material.

• 1. Polymerase Chain Reaction (PCR): Considered the gold standard for Mycoplasma detection.
  • Advantages: Highly sensitive and specific, rapid molecular detection. Can detect more than 90% of known Mycoplasma species. Requires no transport medium if samples are processed quickly.
  • Sample Types: Throat swabs, nasopharyngeal aspirates, bronchoalveolar lavage, urine, genital swabs.
  • Procedure: Involves extracting DNA, amplifying specific Mycoplasma genetic sequences (e.g., 16S rRNA gene) using species-specific primers, and detecting the amplified product (e.g., via gel electrophoresis or qPCR).
  • Rapid Molecular Detection Platforms: Systems like MilliPROBE offer rapid turnaround times (around 4 hours) by directly detecting Mycoplasma nucleic acids.
• 2. Culture: Historically important but rarely performed clinically for routine diagnosis due to significant limitations.
  • Challenges:
    • Slow Growth Rate: Days to weeks for visible colonies (e.g., 6-20 days for M. pneumoniae).
    • Fastidious Requirements: Needs highly enriched specialized media (PPLO, SP-4, Hayflick medium) containing sterols.
    • Strict Atmospheric Control: Requires and optimized temperature ().
    • Low Sensitivity: Not very effective for routine clinical samples.
    • Overgrowth by Contaminants: Other bacteria can easily outcompete Mycoplasma in culture.
    • No Gram Stain: Due to the lack of a cell wall, Mycoplasma cannot be reliably stained with Gram stain.
    • Expertise Required: Requires experienced laboratory personnel for isolation and identification.
  • Colony Morphology: Mycoplasma colonies often exhibit a "fried egg" appearance on agar plates (a dense center with a thinner, lighter periphery), but some species can appear small and spherical.
  • Usage: Primarily used for research, antibiotic susceptibility testing, or when PCR is unavailable/negative but suspicion remains high.
• 3. Indirect Immunofluorescence (IIF): Used for respiratory antigen detection in early-stage infection, but mainly for research.

3.2. Indirect Diagnosis: Serological Testing

Serological tests detect antibodies produced by the host immune system in response to Mycoplasma infection.

• Methods:
  • ELISA (Enzyme-Linked Immunosorbent Assay): Can detect IgM, IgG, and IgA antibodies. Often the method of choice for serology. IgM indicates a recent infection, while IgG indicates past or late infection.
  • Complement Fixation Test (CFT): A traditional assay that detects antibodies. A four-fold rise in antibody titer between acute and convalescent sera (2-4 weeks apart) is indicative of current infection.
  • Agglutination Tests: Detect antibodies that cause Mycoplasma antigens to clump together.
  • Immunofluorescent Antibody (IFA): Measures IgG and IgM separately.
• Interpretation: Requires paired sera (acute and convalescent phase) for definitive diagnosis, as a single titer might reflect past exposure.
• Limitations:
  • Delayed Positivity: Antibody production takes time, leading to delayed diagnosis.
  • Cross-Reactivity: Antibodies may cross-react with other organisms or even host components (e.g., cold agglutinins).
  • Cannot Distinguish Colonization vs. Infection: The presence of antibodies doesn't always mean active disease, especially for species that can be asymptomatic colonizers.
  • Limited Value in Immunocompromised Patients: These patients may not mount a robust antibody response.
  • Persistent IgM: IgM levels can remain elevated for up to a year, complicating the identification of acute infection.

3.3. Comparison of Diagnostic Methods for Mycoplasma pneumoniae

Detection Method	Mycoplasma pneumoniae	Notes
Nonserologic
Culture	Traditionally difficult	Slow, low sensitivity, rarely used clinically
Indirect immunofluorescence	Respiratory antigen for early-stage infection	Research use only but promising
Polymerase chain reaction (PCR)	Assays are being evaluated (gold standard)	High sensitivity and specificity, rapid
Serologic
Complement fixation (CFT)	Traditional assay but seroconvert; need fourfold rise between acute-phase and convalescent sera; >32 single titer may be suggestive	Delayed, requires paired sera
Immunofluorescent antibody	Measures IgG and IgM separately
Latex agglutination	IgM/IgG
Enzyme immunoassay (EIA/ELISA)	Method of choice. Reactive IgM, IgG, and IgA, but IgM level may remain elevated for 1 year	Delayed, cross-reactivity, cannot distinguish colonization vs. infection

4. Treatment Principles and Prevention

Treatment of Mycoplasma infections focuses on specific antibiotics due to their unique cell wall deficiency, which renders many common antibiotics ineffective. Prevention strategies are primarily aimed at reducing transmission.

4.1. Antibiotic Sensitivity and Treatment

• Natural Resistance: Mycoplasmas are naturally resistant to β-lactam antibiotics (e.g., penicillin, cephalosporins) and other antibiotics that target peptidoglycan biosynthesis because they lack a cell wall.
• Effective Antibiotics:
  • Macrolides, Lincosamides, Streptogramins, Ketolides (MLSK): These antibiotics inhibit protein synthesis by binding to the bacterial ribosome. Examples include azithromycin, clarithromycin, and erythromycin. They are often the first-line treatment, especially for M. pneumoniae.
  • Tetracyclines: (e.g., doxycycline) Also inhibit protein synthesis. They are effective against Mycoplasma species but are generally avoided in young children due to effects on bone and tooth development.
  • Fluoroquinolones: (e.g., levofloxacin, moxifloxacin) These antibiotics inhibit bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication. They are effective but often reserved for cases where other treatments fail or in adults.
• General Treatment: Beyond specific antibiotics, general supportive care is crucial, especially for respiratory infections. This includes staying hydrated, ensuring adequate nutritional intake, and getting plenty of rest.
• Importance of Proper Medical Attention: It is crucial to seek proper medical attention and avoid antibiotic abuse to prevent the development of antibiotic resistance.

4.2. Prevention and Safety

Preventative measures for Mycoplasma infections, particularly respiratory ones, align with general infection control practices:

• Hand Hygiene: Frequent hand washing and sanitizing are essential to reduce the spread of respiratory pathogens.
• Surface Disinfection: Disinfecting high-touch surfaces can limit indirect transmission.
• Respiratory Etiquette: Covering coughs and sneezes with an elbow or tissue and disposing of tissues immediately helps contain respiratory droplets.
• Mask Wearing: Wearing a surgical mask or N95 mask when sick or advised can prevent spread.
• Ventilation and Crowd Reduction: Maintaining indoor ventilation and reducing crowd gathering can minimize transmission in enclosed spaces.
• Physical Fitness: Adhering to moderate exercise to enhance physical fitness may contribute to a stronger immune response.

Summary

Mycoplasma species are unique bacteria characterized by the absence of a cell wall, rendering them resistant to β-lactam antibiotics. They are the smallest free-living prokaryotes and possess a sterol-containing membrane. They are obligate parasites, colonizing mucosal surfaces of the respiratory and urogenital tracts. Key pathogens include M. pneumoniae, causing atypical pneumonia and upper respiratory infections, and M. hominis and Ureaplasma urealyticum, associated with urogenital tract infections like PID and NGU.

Pathogenicity involves specialized adhesins, variable surface proteins, the CARDS toxin, hydrogen peroxide production, and biofilm formation, allowing them to evade host defenses and cause tissue damage. Diagnosis relies heavily on PCR as the gold standard due to its sensitivity and specificity, while culture is rarely used clinically because of slow growth and fastidious requirements. Serological tests, like ELISA and CFT, can detect antibody responses but have limitations such as delayed positivity and cross-reactivity.

Treatment primarily involves antibiotics that inhibit protein or DNA synthesis, such as macrolides, tetracyclines, and fluoroquinolones. Prevention emphasizes good hygiene, respiratory etiquette, and reducing exposure to infected individuals.